TEST BANK For Pharmacotherapeutics for Advanced Practice Nurse Prescribers, 6th Edition by Woo & Wright, ISBN13: 9781719648035, All 1-57 Chapters, Verified Latest Edition With Complete Solution Guide A+.

,Test Bank Pharmacotherapeutics forAdvanced Practice Nurse Prescribers 6e Teri Moser Woo
ij ij ij ij ij ij ij ij ij ij ij




Woo 1
Pharmacotherapeutics for APN Prescribers, 6e ij ij ij ij Ch01


Chapter 1. The Role of the Advanced Practice Nurse as Prescriber
ij ij ij ij ij ij ij ij ij ij




MULTIPLE CHOICE ij




1. Nurse practitioner prescriptive authority is regulated by:
ij ij ij ij ij ij



A. The National Council of State Boards of Nursing
ij ij ij ij ij ij ij



B. The U.S. Drug Enforcement Administration
ij ij ij ij



C. The State Board of Nursing for each state
ij ij ij ij ij ij ij



D. The State Board of Pharmacy ij ij ij ij




ANS: i j C PTS: i j 1

2. The benefits to the patient of having an advanced practice registered nurse (APRN)
ij ij ij ij ij ij ij ij ij ij ij ij



prescriberinclude:
ij ij



A. Nurses know more about pharmacology than other prescribers because they take
ij ij ij ij ij ij ij ij ij ij



itboth in their basic nursing program and in their APRN program.
ij ij ij ij ij ij ij ij ij ij ij ij



B. Nurses care for the patient from a holistic approach and include the patient
ij ij ij ij ij ij ij ij ij ij ij ij



indecision-making regarding their care.
ij ij ij ij ij



C. APRNs are less likely to prescribe narcotics and other controlled substances.
ij ij ij ij ij ij ij ij ij ij



D. APRNs are able to prescribe independently in all states, whereas a
ij ij ij ij ij ij ij ij ij ij



physician’sassistant needs to have a physician supervising their practice.
ij ij ij ij ij ij ij ij ij ij




ANS: i j B PTS: i j 1

3. Clinical judgment in prescribing includes:
ij ij ij ij



A. Factoring in the cost to the patient of the medication prescribed ij ij ij ij ij ij ij ij ij ij



B. Always prescribing the newest medication available for the disease process
ij ij ij ij ij ij ij ij ij



C. Handing out drug samples to poor patients ij ij ij ij ij ij



D. Prescribing all generic medications to cut costs ij ij ij ij ij ij




ANS: i j A PTS: i j 1

4. The process for choosing an effective drug for a disorder includes:
ij ij ij ij ij ij ij ij ij ij



A. Asking the patient what drug they think would work best for them
ij ij ij ij ij ij ij ij ij ij ij



B. Consulting nationally recognized guidelines for disease management ij ij ij ij ij ij



C. Prescribing medications that are available as samples before writing a prescription ij ij ij ij ij ij ij ij ij ij



D. Following U.S. Drug Enforcement Administration guidelines for prescribing ij ij ij ij ij ij ij




ANS: i j B PTS: i j 1

5. Nonintentional nonadherence of drug therapy may occur due to: ij ij ij ij ij ij ij ij



A. Belief that medication does not work ij ij ij ij ij



B. Adverse drug reactions ij ij



C. Chronic conditions that require daily therapy ij ij ij ij ij



D. Forgetfulness or distraction ij ij




ANS: i j D PTS: i j 1

, Woo 1
Pharmacotherapeutics for APN Prescribers, 6e ij ij ij ij Ch02


Chapter 2. Review of Basic Principles of Pharmacology
ij ij ij ij ij ij ij




MULTIPLE CHOICE ij




1. A patient’s nutritional intake and laboratory results reflect hypoalbuminemia. This is criticalto
ij ij ij ij ij ij ij ij ij ij ij ij



ij prescribing because: ij



A. Distribution of drugs to target tissue may be affected. ij ij ij ij ij ij ij ij



B. The solubility of the drug will not match the site of absorption.
ij ij ij ij ij ij ij ij ij ij ij



C. There will be less free drug available to generate an effect.
ij ij ij ij ij ij ij ij ij ij



D. Drugs bound to albumin are readily excreted by the kidneys. ij ij ij ij ij ij ij ij ij




ANS: i j A PTS: i j 1

2. Drugs that have a significant first-pass effect:
ij ij ij ij ij ij



A. Must be given by the enteral (oral) route only ij ij ij ij ij ij ij ij



B. Bypass the hepatic circulation ij ij ij



C. Are rapidly metabolized by the liver and may have little, if any, desired action
ij ij ij ij ij ij ij ij ij ij ij ij ij



D. Are converted by the liver to more active and fat-soluble forms
ij ij ij ij ij ij ij ij ij ij




ANS: i j C PTS: i j 1

3. The route of excretion of a volatile drug will likely be the:
ij ij ij ij ij ij ij ij ij ij ij



A. Kidneys
B. Lungs
C. Bile and feces ij ij



D. Skin
ANS: i j B PTS: i j 1

4. A major disadvantage to IV administration is that:
ij ij ij ij ij ij ij



A. First-pass metabolism is eliminated. ij ij ij



B. Needles and sterility are required. ij ij ij ij



C. Absorption of the drug cannot be slowed after administration. ij ij ij ij ij ij ij ij



D. It is significantly more expensive than other routes.
ij ij ij ij ij ij ij




ANS: i j C PTS: ij ij i j 1

5. The nurse practitioner (NP) chooses to give cephalexin every 8 hours based on knowledge
ij ij ij ij ij ij ij ij ij ij ij ij ij



ij ofthe drug’s:
ij ij



A. Propensity to go to the target receptor ij ij ij ij ij ij



B. Biological half-life ij



C. Pharmacodynamics
D. Safety and side effects ij ij ij




ANS: i j B PTS: i j 1

6. Deferasirox is a chelating agent used to treat iron overload by binding iron to render
ij ij ij ij ij ij ij ij ij ij ij ij ij ij



ij itbiologically inactive. This is best characterized as a(n):
ij ij ij ij ij ij ij ij

, Woo 2
Pharmacotherapeutics for APN Prescribers, 6e ij ij ij ij Ch02


A. Nonreceptor mechanism ij



B. Partial agonist ij



C. Full agonist ij



D. Noncompetitive antagonist ij




ANS: i j A PTS: i j 1

7. The point in time on the drug concentration curve that indicates the first sign of a
ij ij ij ij ij ij ij ij ij ij ij ij ij ij ij



therapeuticeffect is the:
ij ij ij ij



A. Minimum adverse effect level ij ij ij



B. Peak of action ij ij



C. Onset of action ij ij



D. Therapeutic range ij




ANS: i j C PTS: i j 1

8. Phenytoin requires that a trough level be drawn. Peak and trough levels are done:
ij ij ij ij ij ij ij ij ij ij ij ij ij



A. When the drug has a wide therapeutic range ij ij ij ij ij ij ij



B. When the drug will be administered for a short time only
ij ij ij ij ij ij ij ij ij ij



C. When there is a high correlation between the dose and saturation of receptor sites
ij ij ij ij ij ij ij ij ij ij ij ij ij



D. To determine if a drug is in the therapeutic range
ij ij ij ij ij ij ij ij ij




ANS: i j D PTS: i j 1

9. A laboratory result indicates that the peak level for a drug is above the minimum
ij ij ij ij ij ij ij ij ij ij ij ij ij ij



toxicconcentration. This means that the:
ij ij ij ij ij ij



A. Concentration will produce therapeutic effects. ij ij ij ij



B. Concentration will produce an adverse response. ij ij ij ij ij



C. Time between doses must be shortened. ij ij ij ij ij



D. Duration of action of the drug is too long. ij ij ij ij ij ij ij ij




ANS: i j B PTS: i j 1

10. Drugs that are receptor agonists may demonstrate what property?
ij ij ij ij ij ij ij ij



A. Irreversible binding to the drug receptor site ij ij ij ij ij ij



B. Up-regulation with chronic use ij ij ij



C. Desensitization or down-regulation with continuous use ij ij ij ij ij



D. Inverse relationship between drug concentration and drug actionij ij ij ij ij ij ij




ANS: i j C PTS: i j 1

11. Drugs that are receptor antagonists, such as beta blockers, may cause:
ij ij ij ij ij ij ij ij ij ij



A. Down-regulation of the drug receptor ij ij ij ij



B. An exaggerated response if abruptly discontinued
ij ij ij ij ij



C. Partial blockade of the effects of agonist drugs ij ij ij ij ij ij ij



D. An exaggerated response to competitive drug agonists
ij ij ij ij ij ij




ANS: i j B PTS: i j 1